occurring after a minimum of 90 days and within 2 years of treatment initiation. Sensitivity analyses used 1:1 propensity ...

Zymeworks is on track to advance five drug candidates into clinical trials in solid tumors including gynecological, thoracic, and digestive system cancers by the first half of 2026. This is ...

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) ...

Interleukin-2 (IL-2) is a well-known cytokine that plays a crucial role in stimulating immune cells, including natural killer (NK) cells and cytotoxic T cells. It has been studied as an immunotherapy ...

HELSINKI, Finland, Dec. 05, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it will be ...

At closing Coherus will pay $49.1 million to buy out the right to receive royalties on net sales of UDENYCA in accordance with the Revenue Participation Right and Sale Agreement with Coduet Royalty ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their ...